Cargando…

Overexpression of miR-125a in Myelodysplastic Syndrome CD34(+) Cells Modulates NF-κB Activation and Enhances Erythroid Differentiation Arrest

Myelodysplastic syndromes (MDS) are characterized by impaired proliferation and differentiation of hematopoietic stem cells. The participation of toll-like receptor (TLR)-mediated signaling in MDS is well documented. Increased TLR signaling leads to the constitutive activation of NF-κB, which mediat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gañán-Gómez, Irene, Wei, Yue, Yang, Hui, Pierce, Sherry, Bueso-Ramos, Carlos, Calin, George, Boyano-Adánez, María del Carmen, García-Manero, Guillermo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972113/ https://www.ncbi.nlm.nih.gov/pubmed/24690917 http://dx.doi.org/10.1371/journal.pone.0093404

Ejemplares similares

Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes
por: Dimicoli, Sophie, et al.
Publicado: (2013)

P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS
por: Bazinet, Alexandre, et al.
Publicado: (2023)

P743: CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes
por: Meunier, Mathieu, et al.
Publicado: (2017)

Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2019)

Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia
por: Ye, Dongjiu, et al.
Publicado: (2008)

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2018)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
por: Urrutia, Samuel, et al.
Publicado: (2023)

An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome
por: Ebert, Benjamin L, et al.
Publicado: (2008)

Disruption of erythroid nuclear opening and histone release in myelodysplastic syndromes
por: Zhao, Baobing, et al.
Publicado: (2019)

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
por: Yang, Hui, et al.
Publicado: (2013)

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
por: DiNardo, Courtney D, et al.
Publicado: (2015)

Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)

Myelodysplastic Syndrome with Erythroid Aplasia following Pure Red Cell Aplasia
por: Kim, Hyoung Doo, et al.
Publicado: (2004)

A Case of Relapsing Polychondritis Associated with Myelodysplastic Syndrome with Erythroid Hypoplasia/Aplasia
por: Heo, Seong-Wook, et al.
Publicado: (2003)

Impaired Mitophagy of Nucleated Erythroid Cells Leads to Anemia in Patients with Myelodysplastic Syndromes
por: Jiang, Huijuan, et al.
Publicado: (2018)

Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment strategy
por: DiNardo, CD, et al.
Publicado: (2014)

High expression of APAF-1 elevates erythroid apoptosis in iron overload myelodysplastic syndrome
por: Gu, Shucheng, et al.
Publicado: (2013)

A three-dimensional in vitro model of erythropoiesis recapitulates erythroid failure in myelodysplastic syndromes
por: Elvarsdóttir, Edda María, et al.
Publicado: (2019)

Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation
por: Rodriguez-Sevilla, Juan Jose, et al.
Publicado: (2023)

Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes
por: Chen, Nianhang, et al.
Publicado: (2020)

p38 MAPK in MDS
por: Gañán‐Gómez, Irene, et al.
Publicado: (2015)

RUNX3 overexpression inhibits normal human erythroid development
por: Menezes, Ana Catarina, et al.
Publicado: (2022)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

Isolation, culture, and immunophenotypic analysis of bone marrow HSPCs from patients with myelodysplastic syndromes
por: Ganan-Gomez, Irene, et al.
Publicado: (2022)

Arsenic Primes Human Bone Marrow CD34+ Cells for Erythroid Differentiation
por: Zhang, Yuanyuan, et al.
Publicado: (2015)

P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE
por: Chien, Kelly, et al.
Publicado: (2023)

Constitutive Activation of the Canonical NF-κB Pathway Leads to Bone Marrow Failure and Induction of Erythroid Signature in Hematopoietic Stem Cells
por: Nakagawa, Masahiro Marshall, et al.
Publicado: (2018)

Overexpression of IκB⍺ modulates NF-κB activation of inflammatory target gene expression
por: Downton, Polly, et al.
Publicado: (2023)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2021)

Effect of platelet-activating factor on the growth of human erythroid and myeloid CD34+ progenitors.
por: Dupuis, F, et al.
Publicado: (1998)

Mutant N-RAS Induces Erythroid Lineage Dysplasia in Human CD34(+) Cells
por: Darley, Richard L., et al.
Publicado: (1997)

Activation of NF-κB driven inflammatory programs in mesenchymal elements attenuates hematopoiesis in low-risk myelodysplastic syndromes
por: Ping, Zhen, et al.
Publicado: (2018)

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
por: Daver, Naval, et al.
Publicado: (2017)

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
por: Ganan-Gomez, Irene, et al.
Publicado: (2022)

GPR125 positively regulates osteoclastogenesis potentially through AKT-NF-κB and MAPK signaling pathways
por: Tang, Chen-Yi, et al.
Publicado: (2022)

Accurate Detection of Uniparental Disomy and Microdeletions by SNP Array Analysis in Myelodysplastic Syndromes with Normal Cytogenetics
por: Heinrichs, Stefan, et al.
Publicado: (2009)

High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance
por: Yang, Hui, et al.
Publicado: (2022)

P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX
por: Bazinet, Alexandre, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l588rsto5ls13fu5lqbrhdadhs